Athersys Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Athersys (ATHX) Misses Q2 EPS by 2c
August 10, 2020 4:01 PM EDTAthersys (NASDAQ: ATHX) reported Q2 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $1.06 million.
Highlights of the second quarter of 2020 and recent events include:
Initiated and advanced enrollment in the Phase 2/3 COVID-19 induced acute respiratory distress syndrome (ARDS) clinical trial (the MACOVIA study) and currently evaluating the safety, tolerability and dose levels of MultiStem® cell therapy in this indication;Continued interactions with the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential collaboration;HEALIOS... More